Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. 2018

Ibrahim Aldoss, and Dongyun Yang, and Ahmed Aribi, and Haris Ali, and Karamjeet Sandhu, and Monzr M Al Malki, and Matthew Mei, and Amandeep Salhotra, and Samer Khaled, and Ryotaro Nakamura, and David Snyder, and Margaret O'Donnell, and Anthony S Stein, and Stephen J Forman, and Guido Marcucci, and Vinod Pullarkat
Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.

UI MeSH Term Description Entries
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077209 Decitabine An azacitidine derivative and antineoplastic antimetabolite. It inhibits DNA methyltransferase to re-activate silent genes, limiting METASTASIS and NEOPLASM DRUG RESISTANCE. Decitabine is used in the treatment of MYELODISPLASTIC SYNDROMES, and ACUTE MYELOID LEUKEMIA. 2'-Deoxy-5-azacytidine,5-Aza-2'-deoxycytidine,5-AzadC,5-Azadeoxycytidine,5-Deoxyazacytidine,5AzadC,AzadC Compound,Dacogen,Decitabine Mesylate,NSC 127716,NSC-127716,2' Deoxy 5 azacytidine,5 Aza 2' deoxycytidine,5 Azadeoxycytidine,5 Deoxyazacytidine,Compound, AzadC,Mesylate, Decitabine,NSC127716
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug
D019086 Bridged Bicyclo Compounds, Heterocyclic Heterocyclic compounds that contain two rings that share two non-adjacent atoms in common. Bicyclo Compounds, Heterocyclic,Heterocyclic Cpds, Bicyclic,Bicyclic Heterocyclic Compounds,Heterocyclic Bicyclo Compounds,Bicyclic Heterocyclic Cpds,Heterocyclic Compounds, Bicyclic

Related Publications

Ibrahim Aldoss, and Dongyun Yang, and Ahmed Aribi, and Haris Ali, and Karamjeet Sandhu, and Monzr M Al Malki, and Matthew Mei, and Amandeep Salhotra, and Samer Khaled, and Ryotaro Nakamura, and David Snyder, and Margaret O'Donnell, and Anthony S Stein, and Stephen J Forman, and Guido Marcucci, and Vinod Pullarkat
July 2022, Leukemia & lymphoma,
Ibrahim Aldoss, and Dongyun Yang, and Ahmed Aribi, and Haris Ali, and Karamjeet Sandhu, and Monzr M Al Malki, and Matthew Mei, and Amandeep Salhotra, and Samer Khaled, and Ryotaro Nakamura, and David Snyder, and Margaret O'Donnell, and Anthony S Stein, and Stephen J Forman, and Guido Marcucci, and Vinod Pullarkat
January 2021, Therapeutic advances in hematology,
Ibrahim Aldoss, and Dongyun Yang, and Ahmed Aribi, and Haris Ali, and Karamjeet Sandhu, and Monzr M Al Malki, and Matthew Mei, and Amandeep Salhotra, and Samer Khaled, and Ryotaro Nakamura, and David Snyder, and Margaret O'Donnell, and Anthony S Stein, and Stephen J Forman, and Guido Marcucci, and Vinod Pullarkat
January 2021, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
Ibrahim Aldoss, and Dongyun Yang, and Ahmed Aribi, and Haris Ali, and Karamjeet Sandhu, and Monzr M Al Malki, and Matthew Mei, and Amandeep Salhotra, and Samer Khaled, and Ryotaro Nakamura, and David Snyder, and Margaret O'Donnell, and Anthony S Stein, and Stephen J Forman, and Guido Marcucci, and Vinod Pullarkat
January 2024, Frontiers in oncology,
Ibrahim Aldoss, and Dongyun Yang, and Ahmed Aribi, and Haris Ali, and Karamjeet Sandhu, and Monzr M Al Malki, and Matthew Mei, and Amandeep Salhotra, and Samer Khaled, and Ryotaro Nakamura, and David Snyder, and Margaret O'Donnell, and Anthony S Stein, and Stephen J Forman, and Guido Marcucci, and Vinod Pullarkat
March 2023, Journal of internal medicine,
Ibrahim Aldoss, and Dongyun Yang, and Ahmed Aribi, and Haris Ali, and Karamjeet Sandhu, and Monzr M Al Malki, and Matthew Mei, and Amandeep Salhotra, and Samer Khaled, and Ryotaro Nakamura, and David Snyder, and Margaret O'Donnell, and Anthony S Stein, and Stephen J Forman, and Guido Marcucci, and Vinod Pullarkat
February 2021, Clinical advances in hematology & oncology : H&O,
Ibrahim Aldoss, and Dongyun Yang, and Ahmed Aribi, and Haris Ali, and Karamjeet Sandhu, and Monzr M Al Malki, and Matthew Mei, and Amandeep Salhotra, and Samer Khaled, and Ryotaro Nakamura, and David Snyder, and Margaret O'Donnell, and Anthony S Stein, and Stephen J Forman, and Guido Marcucci, and Vinod Pullarkat
November 2020, Medicine,
Ibrahim Aldoss, and Dongyun Yang, and Ahmed Aribi, and Haris Ali, and Karamjeet Sandhu, and Monzr M Al Malki, and Matthew Mei, and Amandeep Salhotra, and Samer Khaled, and Ryotaro Nakamura, and David Snyder, and Margaret O'Donnell, and Anthony S Stein, and Stephen J Forman, and Guido Marcucci, and Vinod Pullarkat
December 2023, Hematology (Amsterdam, Netherlands),
Ibrahim Aldoss, and Dongyun Yang, and Ahmed Aribi, and Haris Ali, and Karamjeet Sandhu, and Monzr M Al Malki, and Matthew Mei, and Amandeep Salhotra, and Samer Khaled, and Ryotaro Nakamura, and David Snyder, and Margaret O'Donnell, and Anthony S Stein, and Stephen J Forman, and Guido Marcucci, and Vinod Pullarkat
March 2024, Haematologica,
Ibrahim Aldoss, and Dongyun Yang, and Ahmed Aribi, and Haris Ali, and Karamjeet Sandhu, and Monzr M Al Malki, and Matthew Mei, and Amandeep Salhotra, and Samer Khaled, and Ryotaro Nakamura, and David Snyder, and Margaret O'Donnell, and Anthony S Stein, and Stephen J Forman, and Guido Marcucci, and Vinod Pullarkat
June 2024, Clinical lymphoma, myeloma & leukemia,
Copied contents to your clipboard!